Triple-Negative Breast Cancer: Early Assessment with F-18-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse

David Groheux; Elif Hindie; Sylvie Giacchetti; Marc Delord; Anne-Sophie Hamy; Anne de Roquancourt; Laetitia Vercellino; Nathalie Berenger; Michel Marty; Marc Espie

doi:10.2967/jnumed.111.094045

Triple-Negative Breast Cancer: Early Assessment with F-18-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse

David Groheux
, Elif Hindie
, Sylvie Giacchetti
, Marc Delord
, Anne-Sophie Hamy
, Anne de Roquancourt
, Laetitia Vercellino
, Nathalie Berenger
, Michel Marty
, Marc Espie

Population Health Sciences

Research output: Contribution to journal › Article › peer-review

95 Citations (Scopus)

Original language	English
Pages (from-to)	249-254
Journal	Journal of Nuclear Medicine
Volume	53
Issue number	2
DOIs	https://doi.org/10.2967/jnumed.111.094045
Publication status	Published - Feb 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

F-18-FDG PET/CT
triple-negative breast cancer
neoadjuvant chemotherapy
metabolic response
prognosis

Access to Document

10.2967/jnumed.111.094045

Cite this

Groheux, D., Hindie, E., Giacchetti, S., Delord, M., Hamy, A.-S., de Roquancourt, A., Vercellino, L., Berenger, N., Marty, M., & Espie, M. (2012). Triple-Negative Breast Cancer: Early Assessment with F-18-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse. Journal of Nuclear Medicine, 53(2), 249-254. https://doi.org/10.2967/jnumed.111.094045

@article{1d68b7b692e5478c81e26032b9dff71b,

title = "Triple-Negative Breast Cancer: Early Assessment with F-18-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse",

keywords = "F-18-FDG PET/CT, triple-negative breast cancer, neoadjuvant chemotherapy, metabolic response, prognosis",

author = "David Groheux and Elif Hindie and Sylvie Giacchetti and Marc Delord and Anne-Sophie Hamy and \{de Roquancourt\}, Anne and Laetitia Vercellino and Nathalie Berenger and Michel Marty and Marc Espie",

year = "2012",

month = feb,

doi = "10.2967/jnumed.111.094045",

language = "English",

volume = "53",

pages = "249--254",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "2",

}

Groheux, D, Hindie, E, Giacchetti, S, Delord, M, Hamy, A-S, de Roquancourt, A, Vercellino, L, Berenger, N, Marty, M & Espie, M 2012, 'Triple-Negative Breast Cancer: Early Assessment with F-18-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse', Journal of Nuclear Medicine, vol. 53, no. 2, pp. 249-254. https://doi.org/10.2967/jnumed.111.094045

Triple-Negative Breast Cancer: Early Assessment with F-18-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse. / Groheux, David; Hindie, Elif; Giacchetti, Sylvie et al.
In: Journal of Nuclear Medicine, Vol. 53, No. 2, 02.2012, p. 249-254.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Triple-Negative Breast Cancer: Early Assessment with F-18-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse

AU - Groheux, David

AU - Hindie, Elif

AU - Giacchetti, Sylvie

AU - Delord, Marc

AU - Hamy, Anne-Sophie

AU - de Roquancourt, Anne

AU - Vercellino, Laetitia

AU - Berenger, Nathalie

AU - Marty, Michel

AU - Espie, Marc

PY - 2012/2

Y1 - 2012/2

KW - F-18-FDG PET/CT

KW - triple-negative breast cancer

KW - neoadjuvant chemotherapy

KW - metabolic response

KW - prognosis

U2 - 10.2967/jnumed.111.094045

DO - 10.2967/jnumed.111.094045

M3 - Article

SN - 0161-5505

VL - 53

SP - 249

EP - 254

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 2

ER -

Groheux D, Hindie E, Giacchetti S, Delord M, Hamy AS, de Roquancourt A et al. Triple-Negative Breast Cancer: Early Assessment with F-18-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse. Journal of Nuclear Medicine. 2012 Feb;53(2):249-254. doi: 10.2967/jnumed.111.094045